TITILOPE FASIPE to Child
This is a "connection" page, showing publications TITILOPE FASIPE has written about Child.
Connection Strength
0.201
-
Eculizumab for management of hyperhemolysis syndrome in pediatric patients with sickle cell disease: A single-center case series. Pediatr Blood Cancer. 2024 Aug; 71(8):e31061.
Score: 0.052
-
Clinical Practice Patterns in Sickle Cell Disease Treatment: Disease-modifying and Potentially Curative Therapies. J Pediatr Hematol Oncol. 2024 07 01; 46(5):e277-e283.
Score: 0.052
-
Risk factors and co-morbidities in adolescent thromboembolism are different than those in younger children. Thromb Res. 2016 May; 141:178-82.
Score: 0.015
-
Splenic complications in pediatric sickle cell disease: A retrospective cohort review. Pediatr Blood Cancer. 2024 Oct; 71(10):e31219.
Score: 0.013
-
Multi-center retrospective study of children with sickle cell disease admitted to pediatric intensive care units in the United States. Sci Rep. 2023 04 25; 13(1):6758.
Score: 0.012
-
Racial Disparities in Mental Health Disorders in Youth with Chronic Medical Conditions. J Pediatr. 2023 08; 259:113411.
Score: 0.012
-
Sickle Cell Disease: A Review. JAMA. 2022 07 05; 328(1):57-68.
Score: 0.011
-
Severe Pediatric COVID-19 Pneumonia Treated With Adjuvant Anakinra. Hosp Pediatr. 2022 05 01; 12(5):e162-e170.
Score: 0.011
-
Regional anesthesia for sickle cell disease vaso-occlusive crisis: A single-center case series. Pediatr Blood Cancer. 2022 06; 69(6):e29695.
Score: 0.011
-
Novel dose escalation to predict treatment with hydroxyurea (NDEPTH): A randomized controlled trial of a dose-prediction equation to determine maximum tolerated dose of hydroxyurea in pediatric sickle cell disease. Am J Hematol. 2020 09; 95(9):E242-E244.
Score: 0.010